tetano
Editor, Senior Moderator
Emerg Microbes Infect
. 2023 Aug 16;2249130.
doi: 10.1080/22221751.2023.2249130. Online ahead of print. A TLR9 agonist synergistically enhances protective immunity induced by an Alum-adjuvanted H7N9 inactivated whole-virion vaccine
Tsai-Teng Tzeng[SUP] 1 [/SUP], Kit Man Chai[SUP] 1 [/SUP], I-Hua Chen[SUP] 1 [/SUP], Ray-Yuan Chang[SUP] 1 [/SUP], Jen-Rong Chiang[SUP] 1 [/SUP], Shih-Jen Liu[SUP] 1 2 3 [/SUP]
Affiliations
Antigen sparing is an important strategy for pandemic vaccine development because of the limitation of worldwide vaccine production during disease outbreaks. However, several clinical studies have demonstrated that the current aluminum (Alum)-adjuvanted influenza vaccines fail to sufficiently enhance immune responses to meet licensing criteria. Here, we used pandemic H7N9 as a model virus to demonstrate that a 10-fold lower amount of vaccine antigen combined with Alum and TLR9 agonist can provide stronger protective effects than using Alum as the sole adjuvant. We found that the Alum/CpG 1018 combination adjuvant could induce more robust virus-specific humoral immune responses, including higher total IgG production, hemagglutination-inhibiting antibody activity, and neutralizing antibody titers, than the Alum-adjuvanted formulation. Moreover, this combination adjuvant shifted the immune response toward a Th1-biased immune response. Importantly, the Alum/CpG 1018-formulated vaccine could confer better protective immunity against H7N9 challenge than that adjuvanted with Alum alone. Notably, the addition of CpG 1018 to the Alum-adjuvanted H7N9 whole-virion vaccine exhibited an antigen-sparing effect without compromising vaccine efficacy. These findings have significant implications for improving Alum-adjuvanted influenza vaccines using the approved adjuvant CpG 1018 for pandemic preparedness.
Keywords: Aluminum hydroxide; CpG 1018; H7N9; TLR9 agonist; whole-virion vaccine.
. 2023 Aug 16;2249130.
doi: 10.1080/22221751.2023.2249130. Online ahead of print. A TLR9 agonist synergistically enhances protective immunity induced by an Alum-adjuvanted H7N9 inactivated whole-virion vaccine
Tsai-Teng Tzeng[SUP] 1 [/SUP], Kit Man Chai[SUP] 1 [/SUP], I-Hua Chen[SUP] 1 [/SUP], Ray-Yuan Chang[SUP] 1 [/SUP], Jen-Rong Chiang[SUP] 1 [/SUP], Shih-Jen Liu[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 37585273
- DOI: 10.1080/22221751.2023.2249130
Antigen sparing is an important strategy for pandemic vaccine development because of the limitation of worldwide vaccine production during disease outbreaks. However, several clinical studies have demonstrated that the current aluminum (Alum)-adjuvanted influenza vaccines fail to sufficiently enhance immune responses to meet licensing criteria. Here, we used pandemic H7N9 as a model virus to demonstrate that a 10-fold lower amount of vaccine antigen combined with Alum and TLR9 agonist can provide stronger protective effects than using Alum as the sole adjuvant. We found that the Alum/CpG 1018 combination adjuvant could induce more robust virus-specific humoral immune responses, including higher total IgG production, hemagglutination-inhibiting antibody activity, and neutralizing antibody titers, than the Alum-adjuvanted formulation. Moreover, this combination adjuvant shifted the immune response toward a Th1-biased immune response. Importantly, the Alum/CpG 1018-formulated vaccine could confer better protective immunity against H7N9 challenge than that adjuvanted with Alum alone. Notably, the addition of CpG 1018 to the Alum-adjuvanted H7N9 whole-virion vaccine exhibited an antigen-sparing effect without compromising vaccine efficacy. These findings have significant implications for improving Alum-adjuvanted influenza vaccines using the approved adjuvant CpG 1018 for pandemic preparedness.
Keywords: Aluminum hydroxide; CpG 1018; H7N9; TLR9 agonist; whole-virion vaccine.